Breaking barriers with pegvorhyaluronidase alfa

Halozyme is pioneering therapies that remodel the tumor microenvironment to increase accessibility for chemotherapies, immuno-oncology agents, and innate immune cells. Halozyme is developing pegvorhyaluronidase alfa (PEGPH20) to treat pancreatic and other solid tumors.

Go to the profile of Halozyme Therapeutics
Mar 14, 2018
0
0
Page of
Go to the profile of Halozyme Therapeutics

Halozyme Therapeutics

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.

No comments yet.